Skip to main content
. 2022 Mar 30;12(4):851. doi: 10.3390/diagnostics12040851

Figure 5.

Figure 5

[68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET imaging in breast cancer. (A) Representative transverse CT, PET (1 h p.i.) and fused PET/CT images of primary tumor lesion (red arrow) with a high uptake of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 (patient 6) and immunohistochemistry staining for integrin αvβ3 in primary tumor showing intense staining. (B) CT, PET (1 h p.i.) and PET/CT of primary tumor lesion with a low uptake of tracer (patient 7) and immunohistochemistry staining confirming low intensity of integrin αvβ3 staining.